Shots:

• The P-III EXPLORER-HCM study involves assessing Mavacamten vs PBO in 251 patients in a ratio (1:1) with symptomatic oHCM (LVOT gradient ≥50 mmHg and NYHA Class II-III) for 30wks- followed by an 8-week washout
• Results: @30wks. change in KCCQ OSS in greater than PBO arm; KCCQ OSS ≥20 points (36% vs 15%); a greater proportion of patients in the placebo arm had no change or deterioration in their health status
• Mavacamten is an investigational- first-in-class cardiac myosin inhibitor- in patients with oHCM. The findings of the new analysis are published in the Lancet

  Ref: Businesswire | Image: BMS